Daniel Speidel co-founded Breakpoint Therapeutics in June 2019. He brings the company over 20 years of experience in molecular oncology research with a focus on DNA damage responses and as a strategic advisor to the life sciences industry.
As Managing Director, he oversees Breakpoint’s operations and corporate development. Previously, Daniel served as Vice President, Initiative Leader Oncology at Evotec. In this role he led the efforts to spin off Evotec’s most promising DDR projects and form an independent company, which resulted in Breakpoint. Prior to that he was a Group Leader at Children’s Medical Research Institute and Senior Lecturer at the University of Sydney, Australia.
Daniel holds a PhD in Experimental Cancer Research from the University of Hannover and Heinrich-Pette-Institute (now the Leibniz-Institute of Virology) in Hamburg, Germany. A member of various governing boards and a former management consultant, he has worked with McKinsey & Company and others to advise industry and not-for-profit organizations on matters of strategic importance.
As Managing Director, he oversees Breakpoint’s operations and corporate development. Previously, Daniel served as Vice President, Initiative Leader Oncology at Evotec. In this role he led the efforts to spin off Evotec’s most promising DDR projects and form an independent company, which resulted in Breakpoint. Prior to that he was a Group Leader at Children’s Medical Research Institute and Senior Lecturer at the University of Sydney, Australia.
Daniel holds a PhD in Experimental Cancer Research from the University of Hannover and Heinrich-Pette-Institute (now the Leibniz-Institute of Virology) in Hamburg, Germany. A member of various governing boards and a former management consultant, he has worked with McKinsey & Company and others to advise industry and not-for-profit organizations on matters of strategic importance.
Speaking In
12:15 PM - 12:30 PM
Wednesday, June 7
